Page 8 - Healthcare Sector

Metropolis Healthcare Q3 results: PAT down 24% due to Chennai floods

On a sequential basis, the company exhibited a 5.63 per cent decline in revenue along with PAT, which declined by 23.41 per cent

Dr. Lal PathLabs Q3 results: Profit rises 54% to Rs 81.3 cr, revenue up 10%

The October-December quarter encompasses the tail end of the monsoon as well as winter, which brings with them ailments such as influenza and stomach flu

MSME hospitals in the pink of health; revenue, margins to remain healthy

Revenue and margins to remain healthy next financial year, too

Dr Reddy's Lab Q3 results: Net profit rises 11% on strong US, EU sales

For the Indian business in Q3 FY24, the revenue stood at Rs 1,180 crore Y-o-Y with a growth of 5 per cent and a sequential decline of 1 per cent

AI adoption in healthcare to create almost 3 mn jobs by 2028: Report

Demand will be for data scientists, developers and cybersecurity specialists, it says

High starting valuations dampen equity outlook in 2024: Neelesh Surana

Neelesh Surana expresses concerns over the quality of rally in certain smallcap pockets

Interim Budget 2024: What does the healthcare sector expect from Centre?

Interim budget 2024: Here's what the experts of the real estate sector expect from the Centre

Cashless treatment facility to be available across hospitals, says GIC

Currently, only 63 per cent of customers avail cashless treatment, whereas the remaining 47 per cent opt for reimbursement claims

48% of healthcare, pharma firms to use Gen AI solutions in 1 year: Report

Nearly 48 per cent of healthcare and pharma companies surveyed are poised to integrate first-gen AI solutions within one year, an EY report said on Wednesday. The shift is, however, significant in the sector, which has been traditionally conservative in adopting digital technologies, it added. The findings also underline the growing appeal of this emerging technology that has made headlines with its promise of transforming industries. The EY report insights revealed that in healthcare, Gen AI holds the promise of benefiting every facet of the value chain, from clinical services to customer operations and branding. Similarly, in life sciences, the potential of Gen AI applications is poised to expedite the assimilation of cutting-edge technologies across the value chain. According to the report, 60 per cent of survey participants from the healthcare and life sciences sector believe Gen AI will have a significant impact on the entire value chain. "While 28 per cent of healthcare and

Aster DM Healthcare shareholders approve proposal to hive off Gulf biz

Hospital chain Aster DM Healthcare on Tuesday said its shareholders have approved the proposal to hive off its Gulf business in a deal valued at USD 1.01 billion. The proposed resolutions were passed with the requisite majority by shareholders on January 22, the company said in a regulatory filing. Over 99 per cent of the votes polled were in favour of the deal, it added. On November 28 last year, Aster DM Healthcare announced that it would separate its India and Gulf businesses by way of a deal worth over USD 1 billion. The company stated that it has received approval from its board and subsidiary Affinity Holdings Pvt Ltd to separate the India and GCC businesses into two distinct and standalone entities. Under the separation plan, Affinity entered into a definitive agreement with a consortium of investors led by Fajr Capital, a private equity firm headquartered in the UAE, to invest in Aster's GCC business. Upon completion, the separation of the India and GCC businesses will ..

Medi Assist Healthcare shares surge 11%; Nova Agritech IPO subscribed 9.7x

The initial public offering (IPO) of Nova Agritech garnered nearly 10 times subscription on Tuesday, the opening day of the issue. Most of the bids on the first day came from individual investors

Q3 result preview: US, India to aid revenue growth for Pharma Inc

In the healthcare segment, hospitals are expected to post revenue growth of 13 percent during the coverage, while the net profit growth would be around 37 percent, ICICI Securities said in a note

Murugappa Group's CSR subsidiary AMM Foundation completes 100 years

Established a century ago, the AMM Hospital, known locally as the 'oru ruba' (one rupee, which is the fee charged from patients) hospital, has been a beacon of quality healthcare for local community

Medi Assist healthcare IPO subscribed 54% on first day of bidding

Medi Assist covers over 18,000 hospitals across 1,069 cities and 31 states and has 35 insurers as partners

Ahead of IPO, Medi Assist mobilises Rs 351 crore from anchor investors

The company has allotted 84.08 lakh equity shares to 36 funds at Rs 418 apiece, which is also the upper end of the price band, according to a circular uploaded on BSE's website

Medi Assist Healthcare fixes price band for IPO at Rs 397- Rs 418

Bids for the offer can be made for a minimum of 35 equity shares and in multiples of 35 thereafter

Modi Group plans Rs 6,000 crore investment in the next five years

Modi Group, formerly known as BK Modi Group, is planning to invest Rs 6,000 crore in the next five years in two real estate projects, its founder Bhupendra Modi said on Friday. Modi Group will invest Rs 4,000 crore to develop a health city in Saket, Delhi, he said. Besides, the group has also committed to invest Rs 2,000 crore in city development projects at Modipur in Rampur District of Uttar Pradesh. "In the Saket project, it would be a city and hospital and other projects, and at Modipur, we would have city development, where we would build an entire city. Then we have some more place to invest in," Modi said on the sidelines of an event. The group is also investing Rs 2,000 crore outside the country, Modi said, declining to share any information about that. "This would be a total of Rs 8,000 crore, which is around USD one billion," he said, adding that the group has also a presence and business interests outside India. When asked about the funding, he said it would be a mix o

Sun Pharma Advanced Research freezes at 10% upper circuit; up 64% in 8 days

In the medium term, SPARC's pipeline has several inflexion points that can drive significant value for the company.

BDR Pharmaceuticals launches prostate cancer drug in oral solution form

BDR stated since BDENZA is in liquid form, they can't quantify how lower it is compared to its counterparts in the market as they are present in solid form (tablet/capsule)

As Covid-19 cases rise in India; should you keep pharma stocks on radar?

Barring Dr Lal Pathlabs, the other four healthcare related stocks listed below seem to be trapped in a range for now, charts suggest.